Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,188 people get ASTX articles and Market Currents by email alert.

Get email alerts on ASTX »

ASTX

Astex Pharmaceuticals, Inc.

5/22/2013, 8:44 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 1:25 PM Astex Pharmaceutical (ASTX -4.4%) succumbs to profit-taking for a second day on heavy volume, with no real catalyst to explain the move but some small sales reported by its CEO and one of its directors over the past couple days. The sales really aren't too surprising when you take into consideration that the stock has been on a tear since late last year, rising over 225% just since November. 2 Comments [Healthcare, On the Move]
Wednesday, May 1, 12:50 PM Midday top 10 gainers: IQNT +60%. BCOV +31%. CNIT +28%. MNOV +21%. MSPD +19%. SONS +15%. TRLA +15%. RATE +15%. REGN +14%. SGI +14%.
Midday top 10 losers: ACCL -21%. RBC -20%. ESBF -17%. LEDS -16%. KFRC -15%. AGN -14%. CRAY -13%. ASTX -13%. XXIA -13%. UTI -12%. Comment! [On the Move]
Monday, April 29, 6:30 PM Astex Pharmaceuticals (ASTX): Q1 EPS of $0.01 beats by $0.07. Revenue of $22.1M beats by $3.63M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 10, 8:46 AM Astex Pharmaceuticals (ASTX) looks set for a strong session after saying researchers at Indiana University found that the company's SGI-110 DNA-hypomethylating agent "significantly" slowed tumor growth when administered with platinum. Earlier this month, RBC called the drug a "potential blockbuster." ASTX also notes it has expanded an ongoing Phase 2 trial. Shares +2.38% premarket. Comment! [On the Move, Healthcare]
Wednesday, April 3, 11:51 AM Astex Pharmaceuticals (ASTX +12.5%) gets a pop from RBC today, who initiated coverage with an Outperform and a $9 price target, calling it an "undiscovered gem." The firm says the ASTX could have a blockbuster in its pipeline with its experimental blood cancer drug, SGI-110, which is thought to be a safer and more effective version of an already approved therapy it licenses to Eisai (ESALY.PK) and JNJ. ASTX owns all the rights to SGI-110, giving it big upside potential if it gets approved. Additionally, the company reported earlier that it plans to present "significant data" at the AACR annual meeting on Saturday. Comment! [Healthcare, On the Move]
Wednesday, April 3, 9:35 AM Astex Pharmaceuticals (ASTX +10.5%) plans to present "significant data supporting our clinical programs" at the American Association for Cancer Research's (AACR) annual meeting, which starts on Saturday. Astex is due to present preliminary Phase II data for SGI-110, an agent that's being developed for treating cancer. (PR) Comment! [On the Move, Healthcare]
Wednesday, April 3, 9:10 AM Premarket gainers: CALL +14%. CONN +10%. ZNGA +10%. ASTX +10%. UNXL +9%. AWRE +9%. OMPI +9%. NVAX +9%. ALXA +8%. MHR +7%. NFX +6%.
Losers: MSPD -19%. GPN -7%. 3 Comments [On the Move]
Monday, December 10, 2012, 1:06 PM Astex Pharmaceuticals (ASTX +2.8%) moves up after presenting encouraging Phase I clinical results of SGI-110, a novel second generation hypomethylation agent, during a presentation at the American Society of Hematology. Data from the trial showed that patients with acute myelogenous leukemia using the drug demonstrated a differentiated pharmacokinetic profile resulting in an extended half-life and exposure to decitabine. Comment! [Healthcare, On the Move]
Tuesday, November 20, 2012, 1:20 PM Astex Pharmaceuticals (ASTX +12.5%) rallies after saying earlier that Phase I/II testing of its SGI-110 drug candidate showed that it was well tolerated in patients with leukemia or myelodysplastic syndromes at doses higher than the biologically effective dose. Comment! [Healthcare, On the Move]
Friday, September 28, 2012, 9:14 AM The EU puts its OK on drug Dacogen to treat a kind of leukemia, Astex Pharmaceuticals (ASTX) says, calling it "the world's first medicine approved and labeled specifically for elderly acute myeloid leukemia." The firm receives royalties from licensee Eisai - which has marketing and development rights in North America - and expects $17.5M in future payments if milestones continue worldwide. ASTX +9.4% premarket. Comment! [Healthcare, On the Move]
Friday, September 28, 2012, 9:10 AM Premarket gainers: BYFC +42.86%. CYTX +18.91%. RIMM +15.83%. ASTX +8.71%. QCOR +9.03%.
Losers: ADTN -8.14%. CLWR -7.43%. PPHM -5.41%. 2 Comments
Friday, September 21, 2012, 9:02 AM Astex Pharma (ASTX) -9.6% premarket after it discontinues clinical development of amuvatinib because the potential cancer inhibitor fell short of the targeted response rate in platinum-refractory small-cell lung cancer patients. Comment! [Healthcare, On the Move]
Wednesday, March 7, 2012, 9:02 AM Premarket gainers: DSCO +41%. TRCR +39%. CIEN +9%. MAKO +10%. AEO +5%. CTIC +5%. NFLX +5%. RDN +5%. NUAN +3%. ACH +3%. SINA +3%. DRYS +3%.
Losers: P -26%. CSIQ -12%. ASTX -5%. AYR -5%. Comment! [On the Move]
Wednesday, March 7, 2012, 8:17 AM Astex Pharmaceuticals (ASTX) -6% premarket after the FDA declines to approve Dacogen for treatment of acute myeloid leukemia in elderly patients. The decision follows an advisory panel's recommendation last month. Comment! [Healthcare, On the Move]
Thursday, February 9, 2012, 2:17 PM Shares of Astex Pharmaceuticals (ASTX) resume trading down 10.8% off the news that the FDA rejected the use of Dacogen to treat AML in adults over the age of 65. Comment! [On the Move]
Thursday, February 9, 2012, 1:54 PM A FDA panel rejects Eisai's (ESALY.PK) blood drug Dacogen for use as a treatment for leukemia after finding that a study "failed to demonstrate benefit on statistical interpretation." Shares of Dacogen-seller Astex Pharmaceuticals (ASTX) - currently halted - could feel a jolt off the news when trading resumes. Comment! [Healthcare]